Form 4 Filing for Beta Bionics, Inc.

Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc. (BBNX), sold 30,779 shares of common stock on September 16, 2026. The sales were conducted under a Rule 10b5-1 Plan adopted on June 10, 2026. The weighted average sale price was $20.1319, with prices ranging from $20.00 to $20.64. Following these transactions, Mr. Hopman owns 56,479 shares of common stock. Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the Issuer, or any security holder of the Issuer.